{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T08:35:35Z","timestamp":1768725335131,"version":"3.49.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.ijpharm.2011.11.031","type":"journal-article","created":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T11:22:39Z","timestamp":1324034559000},"page":"586-588","source":"Crossref","is-referenced-by-count":31,"title":["In vitro and in vivo evaluation of camptothecin nanosuspension: A novel formulation with high antitumor efficacy and low toxicity"],"prefix":"10.1016","volume":"423","author":[{"given":"Liping","family":"Yao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuhua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuangang","family":"Zu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujie","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baishi","family":"Zu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangdong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2011.11.031_bib0005","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1021\/jp076930n","article-title":"Stable colloidal dispersions of a lipaseperfluoropolyether complex in liquid and supercritical carbon dioxide","volume":"112","author":"Adkins","year":"2008","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.ijpharm.2011.11.031_bib0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00280-002-0539-y","article-title":"Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia","volume":"50","author":"Cortes","year":"2002","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ijpharm.2011.11.031_bib0015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0378-5173(97)00275-5","article-title":"Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion","volume":"159","author":"Cortesi","year":"1997","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2011.11.031_bib0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/0-306-47932-X_9","article-title":"CMdextran\u2013polyalcohol\u2013camptothecin conjugate: DE-310 with a novel carrier system and its preclinical data","volume":"519","author":"Inoue","year":"2003","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ijpharm.2011.11.031_bib0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0928-0987(01)00214-7","article-title":"Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent","volume":"15","author":"Kang","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2011.11.031_bib0030","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/jbm.a.31452","article-title":"A novel polyrotaxane-based intracellular delivery system for camptothecin: in vitro feasibility evaluation","volume":"84A","author":"Moon","year":"2008","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.ijpharm.2011.11.031_bib0035","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ejpb.2004.03.022","article-title":"Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology","volume":"58","author":"Moschwitzer","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2011.11.031_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2011.01.007","article-title":"State of the art of nanocrystals \u2013 special features, production, nanotoxicology aspects and intracellular delivery","volume":"78","author":"M\u00fcller","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2011.11.031_bib0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1021\/np030498t","article-title":"Camptothecin and taxol: historic achievements in natural products research","volume":"67","author":"Oberlies","year":"2004","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ijpharm.2011.11.031_bib0050","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1749-6632.1996.tb26399.x","article-title":"Clinical trials of irinotecan hydrochloride in Japan","volume":"803","author":"Saijo","year":"1996","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.ijpharm.2011.11.031_bib0055","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1002\/jps.21344","article-title":"Use of hydrodynamic flow focusing for the generation of biodegradable camptothecin-loaded polymer microspheres","volume":"97","author":"Schneider","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2011.11.031_bib0060","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1126\/science.2555920","article-title":"DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts","volume":"246","author":"Wall","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.ijpharm.2011.11.031_bib0065","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.supflu.2009.10.004","article-title":"Preparation and characterization of camptothecin powder micronized by a supercritical antisolvent (SAS) process","volume":"51","author":"Zhao","year":"2010","journal-title":"J. Supercrit. Fluids"}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517311010726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517311010726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T19:21:51Z","timestamp":1543346511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517311010726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0378517311010726"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2011.11.031","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}